Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926906 | 0.84 | IDO1 (0.42) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL230691 | 0.83 | HDAC3 (0.41) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL874457 | 0.81 | KDM4E (0.48) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL10715442 | 0.80 | IDO1 (0.42) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1532612 | 0.80 | HDAC3 (0.41) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL7299189 | 0.79 | IDO1 (0.44) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15572500 | 0.79 | KDM4E (0.47) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL1373071 | 0.79 | KDM4E (0.47) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15571571 | 0.79 | KDM4E (0.47) | IDO1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL15572404 | 0.79 | IDO1 (0.48) | IDO1HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111282545-B | Two-dimensional van der waals heterojunction and application thereof | 东南大学 | 2022-03-11 | — | — | CN | claimed |
| CN-113512219-A | Color-adjustable contact lens material and preparation method thereof | 东南大学 | 2021-10-19 | — | — | CN | claimed |
| CN-111282545-A | Two-dimensional van der waals heterojunction and application thereof | 东南大学 | 2020-06-16 | — | — | CN | claimed |
| CN-117680105-A | Energy-consumption-free air water production and precipitation bed and preparation method and application thereof | 东南大学 | 2024-03-12 | — | — | CN | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-113717114-B | 2-acetylpyrazine continuous recrystallization device, method and application thereof | 济南悟通生物科技有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-113351177-B | Humidity capturing gel, preparation method and application | 东南大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-113512219-B | Color-adjustable contact lens material and preparation method thereof | 东南大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
| EP-0119718-B1 | SMOKING COMPOSITIONS CONTAINING A NOVEL MONOACYLPYRAZINE FLAVORANT | Philip Morris Products Inc. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4635652-A | CIGARETTES | PHILIP MORRIS INCORPORATED (US) | 1987-01-13 | — | — | US | disclosed |
| US-4588813-A | 1-pyrazinyl-1-propanone derivatives useful as flavorants in smoking compositions | PHILIP MORRIS INCORPORATED (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0119718-A1 | Smoking compositions containing a novel monoacylpyrazine flavorant | Philip Morris Products Inc. (US) | 1984-09-26 | — | — | EP | disclosed |
| EP-0076085-A1 | Production of monoacylpyrazines | PHILIP MORRIS INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
| US-4303689-A | Flavoring with pyrazine derivatives | FIRMENICH SA (CH) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | IDO1 559/4885HDAC3 2656/4885HDAC1 1418/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | IDO1 3698/4885HDAC3 2140/4885HDAC1 1546/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | IDO1 238/4885HDAC3 123/4885HDAC1 99/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | IDO1 3333/4885HDAC3 491/4885HDAC1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.